Association of serum levels of epidermal growth factor with disease severity in patients with unresectable hepatocellular carcinoma

Abstract

Aim: Epidermal growth factor (EGF) is a mitogen for hepatocyte grown in vitro, and its expression is up-regulated during liver regeneration. EGF also plays an important role in tumor initiation and progression. The goal of this study is to assess whether EGF is associated with advanced hepatocellular carcinoma (HCC) and also whether it is a predictive factor of shortened survival.

Methods: Serum EGF levels were evaluated in a total of 151 subjects: 51 patients with unresectable HCC, (21 of them were eligible for transarterial chemoembolization (TACE) and serum EGF levels were measured before and 1 week after TACE), 40 patients with chronic hepatitis without cirrhosis, 40 patients with cirrhosis, and 20 healthy controls. Patient demographic and laboratory variables were evaluated as predictive factors of survival in a Cox regression multivariate analysis using SPSS software.

Results: The mean serum level of EGF in patients with HCC was 784.49 pg/mL, which was significantly higher (P < 0.05) than all other groups. Mean EGF level in cirrhotic patients was 144.69 pg/mL; in those with chronic hepatitis C without cirrhosis, it was 338.64 pg/mL; and in healthy controls, it was 297.15 pg/mL. In group Ia patients who underwent TACE, the mean serum level of EGF was 759.76 ± 287.88 pg/mL before TACE, and 801.14 ± 276.12 pg/mL 1 week after treatment (P = 0.34). On multivariate Cox regression analysis only age (P = 0.03) and higher serum EGF level (P = 0.005), were inversely correlated with overall survival.

Conclusion: EGF levels were found to be significantly higher in HCC patients and together with age were the only predictors of poor survival in these patients. There was an increase in EGF levels 1 week after TACE in response to hypoxia; however, this increase was not statistically significant.

Keywords

Cirrhosis / epidermal growth factor / hepatocellular carcinoma / survival / transarterial chemoembolization

References

[1] El-Serag HB.Hepatocellular carcinoma..N Engl J Med2011;365:1118-27

[2] Bruix J,Committee Practice Guidelines.Management of hepatocellular carcinoma..Hepatology2005;42:1208-36

[3] Ibrahim AS,Mikhail NN,Kamel H.Cancer incidence in Egypt: results of the national population-based cancer registry program..J Cancer Epidemiol2014;2014:437971

[4] Villanueva A,Toffanin S,Alsinet C,Cornella H.New strategies in hepatocellular carcinoma: genomic prognostic markers..Clin Cancer Res2010;16:4688-94 PMCID:PMC3395071

[5] Teofănescu I,Stefănescu G.Surveillance of cirrhosis for hepatocellular carcinoma-clinical validation of new serological biomarkers for improved diagnosis..Rev Med Chir Soc Med Nat Iasi2010;114:39-46

[6] Zhu AX,Miksad R,Meyerhardt JA,Muzikansky A,Kwak EL,Jors KR,Iafrate AJ,Ryan DP.Phase 1/2 study of everolimus in advanced hepatocellular carcinoma..Cancer2011;117:5094-102 PMCID:PMC3417818

[7] Carmeliet P.Molecular mechanisms and clinical applications of angiogenesis..Nature2011;473:298-307 PMCID:PMC4049445

[8] Zhang L,Tang JM,Yang JY,Guo LY,Zhang L,Cao SF,Guo HL.VEGF is essential for the growth and migration of human hepatocellular carcinoma cells..Mol Biol Rep2012;39:5085-93 PMCID:PMC4354771

[9] González L,Miquet JG,Fernández D,Bartke A.GH modulates hepatic epidermal growth factor signaling in the mouse..J Endocrinol2010;204:299-309 PMCID:PMC4208314

[10] Libermann TA,Bartal AD,Schlessinger J.Expression of epidermal growth factor receptors in human brain tumors..Cancer Res1984;44:753-60

[11] Weichselbaum RR,Beckett MA,Moran WJ,Vokes EE.Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines..Head Neck1989;11:437-42

[12] Borlak J,Halter R,Spanel-Borowski K.Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours..Oncogene2005;24:1809-19

[13] Lee JS.Comparative and integrative functional genomics of HCC..Oncogene2006;25:3801-9

[14] Kannangai R,Torbenson MS.EGFR is phosphorylated at Ty845 in hepatocellular carcinoma..Mod Pathol2006;19:1456-61

[15] Mroczkowski B.Identification of biologically active epidermal growth factor precursor in human fluids and secretions..Endocrinology1993;132:417-25

[16] Shaker MK,Khalifa MO.Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases..Liver Int2013;33:1601-6

[17] Pirisi M,Fabris C,Bardus P,Beltrami CA.Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study..J Cancer Res Clin Oncol1998;124:397-400

[18] Abdel-Wahab M,Mostafa M,El-Sadany M,Salah T.Epidemiology of hepatocellular carcinoma in lower Egypt, Mansoura Gastroenterology Center..Hepatogastroenterology2007;54:157-62

[19] Altekruse SF,Reichman ME.Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005..J Clin Oncol2009;27:1485-91 PMCID:PMC2668555

[20] Lerose R,Rocchi E,Villa E.Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease..Eur J Cancer2001;37:239-45

[21] Shehata F,Sakr M,Balbaa M.Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma..Med Oncol2013;30:673

[22] Klocke R,Ehrhardt A,Donato MT,Castell JV.Establishment and characterization of immortal hepatocytes derived from various transgenic mouse lines..Biochem Biophys Res Commun2002;294:864-71

[23] Inoue K,Nakamura T,Masuda H,Hashimoto O,Ueno T,Sata M.Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice..Clin Cancer Res2012;18:3924-33

[24] Yoneda N,Kitao A,Sawada-Kitamura S,Harada K,Matsui O.Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma..Lab Invest2011;91:262-72

[25] DeCicco LA,Ringer DP.Carcinogen-induced alteration in liver epidermal growth factor receptor distribution during the promotion stage of hepatocarcinogenesis in rat..Cancer Lett1997;111:149-56

[26] Sung TI,Chen CY,Guo HR.Increased serum level of epidermal growth factor receptor in liver cancer patients and its association with exposure to arsenic..Sci Total Environ2012;424:74-8

[27] Wu BW,Wang JL,Yuan SY,Cui WR.Study on the mechanism of epidermal growth factor-induced proliferation of hepatoma cells..World J Gastroenterol2003;9:271-5 PMCID:PMC4611326

[28] Wu F,Li YF,Chen DP.Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma..Hepatology2009;50:1839-50

[29] Iagoda AB,Geĭvandova NI,Kastornaia IV.Growth factors and the hystologic picture of the liver in chronic viral hepatitis and hepatic cirrhosis..Klin Med (Mosk)2006;84:44-7(article in Russian)

[30] Zhong JH,Gong WF,Zhang Y,Wu LC,Li LQ.Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis..PLoS One2012;7:e32159 PMCID:PMC3293888

[31] Tanabe KK,Finkelstein DM,Fujii T,Lauwers GY,Muzikansky A,Lanuti M,Azoulay D.Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis..JAMA2008;299:53-60

[32] Philip PA,Allmer C,Pitot HC,Donehower RC,Picus J.Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer..J Clin Oncol2005;23:6657-63

[33] Bekaii-Saab T,Prescott N,Heerema N,Dai Z,Campbell A,Balint C,Lee RM,Dancey J,Grever M,Villalona-Calero M.A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas..Clin Cancer Res2009;15:5895-901 PMCID:PMC2774354

[34] Sogawa C,Yoshida C,Furukawa T,Akahori Y,Kurosawa G,Saga T.Novel human monoclonal antibody against epidermal growth factor receptor as an imaging probe for hepatocellular carcinoma..Nucl Med Commun2012;33:719-25

[35] Goffin JR.Epidermal growth factor receptor: pathway, therapies, and pipeline..Clin Ther2013;35:1282-303